Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSF management changes

This article was originally published in The Tan Sheet

Executive Summary

NSF announces in its February electronic newsletter three new appointments to its dietary supplement programs. Kristen Holt is now senior VP of NSF's Dietary Supplement Programs, where she is responsible for the "strategic direction and success of NSF's Food Safety and Dietary Supplement Programs," the firm says. Ed Wyszumiala will serve as account manager for the dietary supplement programs, where he will "head NSF's dietary supplements strategic sales initiatives," according to the newsletter. Sarah Ostrosky is the Certification Project Manager for the NSF Dietary Supplement and Functional Food Programs. Ostrosky will "facilitate GMP registration and certification projects," the company says...

You may also be interested in...



NSF Expands Sports Product Testing, Appoints GM At “Crucial Time”

NSF International appointed Edward Wyszumiala Jan. 14 to head the organization's supplement programs as it expands its testing of sports nutrition products for banned substances in response to growing concern about adulterated products

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel